<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16563">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01814709</url>
  </required_header>
  <id_info>
    <org_study_id>GP28617</org_study_id>
    <nct_id>NCT01814709</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label Study to Evaluate the Effect of Rifampin or Itraconazole on the Pharmacokinetics of GDC-0032 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, two-arm, drug interaction study will investigate the effect of
      co-administration of rifampin or itraconazole on the pharmacokinetics of GDC-003 2 in
      healthy volunteers. In Arm A, volunteers will receive GDC-0032 and rifampin

      ; in Arm B, volunteers will receive GDC-0032 and itraconazole. The anticipated t ime on
      study treatment is approximately 30 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Pharmacokinetics: Plasma concentrations of GDC-0032</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Rifampin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Itraconazole Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0032</intervention_name>
    <description>Oral doses of GDC-0032</description>
    <arm_group_label>Rifampin Arm</arm_group_label>
    <arm_group_label>Itraconazole Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Oral doses of Rifampin</description>
    <arm_group_label>Rifampin Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Oral doses of Itraconazole</description>
    <arm_group_label>Itraconazole Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female volunteers will be non-pregnant, non-lactating, and either postmenopausal for
             at least 1 year or surgically sterile

          -  Male volunteers will either be sterile, or agree to use adequate methods of
             contraception

          -  Body mass index (BMI) range 18 to 32 kg/m2, inclusive

          -  No clinically significant findings from medical history, physical examination,
             12-lead ECG, vital signs; and clinical laboratory evaluations

          -  Negative hepatitis B virus, hepatitis C virus and negative HIV antibody screens

        Exclusion Criteria:

          -  Significant history or clinical manifestation of any significant metabolic, allergic,
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
             gastrointestinal, neurological, or psychiatric disorder

          -  History of significant hypersensitivity, intolerance, or allergy to any drug
             compound, food, or other substance

          -  History of stomach or intestinal surgery or resection that would alter absorption
             and/or excretion of orally administered study drugs

          -  History of alcoholism or drug addiction within 1 year prior to Check-in

          -  History of chronic proton pump inhibitor (PPI) use within 6 months of Check-in, or
             use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to Check-in
             and during the entire study

          -  Clinically significant history of liver disease, including viral or other hepatitis,
             current alcohol abuse, or cirrhosis

          -  History type 1 or 2 diabetes and/or elevated fasting glucose at baseline

          -  Malabsorption syndrome or other condition that would interfere with enteral
             absorption

          -  Use of any tobacco- or nicotine containing- products

          -  Participation in any other investigational study drug or biologic agent trial in
             which receipt of an investigational study drug occurred within 5 half-lives or 30
             days, whichever is longer to Check-in and during the entire study duration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
